February 13, 2020 / 12:33 PM / 9 days ago

BRIEF-Genocea Biosciences Expects That Its Existing Cash And Cash Equivalents Are Sufficient To Support Its Operations Into Q1 Of 2021

Feb 13 (Reuters) - Genocea Biosciences Inc:

* GENOCEA BIOSCIENCES INC - EXPECTS THAT ITS EXISTING CASH AND CASH EQUIVALENTS ARE SUFFICIENT TO SUPPORT ITS OPERATIONS INTO Q1 OF 2021

* GENOCEA BIOSCIENCES QTRLY LOSS PER SHARE $0.34 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below